BE2011C028I2 - Macrocyclic analogs and methods of their use and preparation - Google Patents

Macrocyclic analogs and methods of their use and preparation

Info

Publication number
BE2011C028I2
BE2011C028I2 BE2011C028C BE2011C028C BE2011C028I2 BE 2011C028 I2 BE2011C028 I2 BE 2011C028I2 BE 2011C028 C BE2011C028 C BE 2011C028C BE 2011C028 C BE2011C028 C BE 2011C028C BE 2011C028 I2 BE2011C028 I2 BE 2011C028I2
Authority
BE
Belgium
Prior art keywords
preparation
methods
macrocyclic analogs
analogs
macrocyclic
Prior art date
Application number
BE2011C028C
Other languages
French (fr)
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2011C028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BE2011C028I2 publication Critical patent/BE2011C028I2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a compound having the formula: that is useful as an intermediate in the preparation of certain pharmaceutically active halichondrin analogs.
BE2011C028C 1998-06-17 2011-09-02 Macrocyclic analogs and methods of their use and preparation BE2011C028I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
PCT/US1999/013677 WO1999065894A1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation
EP99928746A EP1087960B1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Publications (1)

Publication Number Publication Date
BE2011C028I2 true BE2011C028I2 (en) 2018-08-24

Family

ID=22219026

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2011C028C BE2011C028I2 (en) 1998-06-17 2011-09-02 Macrocyclic analogs and methods of their use and preparation

Country Status (22)

Country Link
US (4) US6214865B1 (en)
EP (4) EP2277873B1 (en)
JP (1) JP4454151B2 (en)
KR (1) KR100798600B1 (en)
CN (1) CN1216051C (en)
AT (1) ATE502932T1 (en)
AU (1) AU762998B2 (en)
BE (1) BE2011C028I2 (en)
BR (1) BRPI9911326B8 (en)
CA (3) CA2335300C (en)
CY (2) CY1111516T1 (en)
DE (2) DE122011100031I1 (en)
DK (1) DK1087960T3 (en)
FR (1) FR11C0038I2 (en)
HU (1) HU227912B1 (en)
IL (1) IL139960A0 (en)
LU (1) LU91854I2 (en)
NO (5) NO328280B1 (en)
NZ (1) NZ508597A (en)
PT (1) PT1087960E (en)
WO (1) WO1999065894A1 (en)
ZA (1) ZA200007159B (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
HU227912B1 (en) * 1998-06-17 2012-05-29 Eisai R & D Man Co Halichondrin analogs and methods of their use and preparation
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE10037310A1 (en) 2000-07-28 2002-02-07 Asta Medica Ag New indole derivatives and their use as medicines
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
CA2479764C (en) 2002-03-22 2013-07-30 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
EP1644008B1 (en) * 2003-05-29 2011-12-21 Abbott Laboratories Continuous dosing regimen with abt-751
EP1653953A4 (en) * 2003-07-29 2010-05-05 Eisai R&D Man Co Ltd Drug delivery methods and devices
PL2522663T3 (en) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Intermediates for the preparation of halichondrin B
CN109180615A (en) * 2004-06-03 2019-01-11 卫材R&D管理有限公司 Intermediates for the preparation of analogs of halichondrin B
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
EP1831697A4 (en) * 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SCREENING OF TUBULIN ISOTYPE IN CANCER THERAPY USING ANALOGUES OF HALICHONDRIN B
CN108948039B (en) 2007-10-03 2021-12-31 卫材R&D管理有限公司 Intermediates and methods for the synthesis of halichondrin B analogs
CN105801599A (en) * 2008-04-04 2016-07-27 卫材R&D管理有限公司 Halichondrin b analogs
HRP20161157T1 (en) 2009-03-30 2016-11-18 Eisai R&D Management Co., Ltd. Liposome composition
RU2476216C1 (en) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Liposomal composition
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
JP5556811B2 (en) * 2009-04-14 2014-07-23 日産化学工業株式会社 Method for producing tetrahydropyran compound
BR112012003592B8 (en) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd pharmaceutical composition containing quinoline derivative
CN102803254B (en) 2010-01-26 2016-09-14 卫材R&D管理有限公司 furo [3,2-B ] pyran derivatives for halichondrin B analog synthesis
WO2012129100A1 (en) 2011-03-18 2012-09-27 Eisai R&D Management Co., Ltd. Methods and compositions for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2857385A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
US9174956B2 (en) 2011-12-16 2015-11-03 Alphora Research Inc. Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
JP6300030B2 (en) * 2011-12-29 2018-03-28 サンド アクツィエンゲゼルシャフト 2-((2S, 3S, 4R, 5R) -5-((S) -3-Amino-2-hydroxyprop-1-yl) -4-methoxy-3- (phenylsulfonylmethyl) tetrahydrofuran-2-yl ) Acetaldehyde derivatives and processes for preparing them
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
MX2015007185A (en) 2012-12-04 2017-09-05 Eisai R&D Man Co Ltd Use of eribulin in the treatment of breast cancer.
AU2014268086A1 (en) 2013-05-15 2015-11-05 Alphora Research Inc. 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
AU2014299699B2 (en) 2013-06-26 2019-10-10 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
CN103483352A (en) * 2013-10-18 2014-01-01 李友香 Medicinal bulk drug for resisting tumors
CN105683198B (en) 2013-11-04 2019-03-12 卫材R&D管理有限公司 Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B
HUE043088T2 (en) * 2013-12-06 2019-08-28 Eisai R&D Man Co Ltd Methods for the synthesis of halicondrin B analogs
CN104860978A (en) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 Synthesis intermediates of halichondrin B analog
TW201617326A (en) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
JP2017516802A (en) 2014-05-28 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Use of eribulin in the treatment of cancer
EP3160970A4 (en) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthesis of halichondrin analogs and uses thereof
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
EP3191479B1 (en) * 2014-09-09 2020-04-08 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
CN105713031B (en) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 Intermediate for preparing eribulin and preparation method thereof
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
KR20170122810A (en) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 A combination of PD-1 antagonist and eribulin for treating cancer
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
RU2020141025A (en) * 2015-05-07 2020-12-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. MACROCYCLIZATION REACTIONS AND INTERMEDIATE COMPOUNDS AND OTHER FRAGMENTS USEFUL IN THE SYNTHESIS OF HALIKHONDRIN MACROLIDES
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
BR112017027227B1 (en) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd ANTI-CANCER AGENT
JP6553726B2 (en) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 Tumor therapeutic agent
US10676481B2 (en) 2016-02-12 2020-06-09 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
WO2017188350A1 (en) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for inhibiting tumor growth
WO2017203459A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
SG11201811671XA (en) 2016-06-30 2019-01-30 Eisai R&D Man Co Ltd Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
EP3525818A1 (en) 2016-10-14 2019-08-21 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (en) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ Palladium-mediated ketolization
WO2018096478A2 (en) 2016-11-23 2018-05-31 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
KR101880939B1 (en) 2017-01-02 2018-08-17 연성정밀화학(주) Intermediate for Preparing Eribulin Mesylate and Process for Preapring the Same
JP6920699B2 (en) * 2017-01-02 2021-08-18 ヨンスン ファイン ケミカル カンパニー，リミテッド Eribulin mesylate production intermediate and its production method
KR101991710B1 (en) 2017-12-14 2019-06-21 연성정밀화학(주) Intermediate for Preparing Eribulin Mesylate and Process for Preparing the Same
CN108341828B (en) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 Process for the preparation of eribulin and intermediates thereof
CN108341738B (en) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 Process for the preparation of eribulin and intermediates thereof
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
KR102836514B1 (en) 2017-04-05 2025-07-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Macrocyclic compound and uses thereof
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
BR112019023064A2 (en) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd treatment of hepatocellular carcinoma
HUE061306T2 (en) 2017-07-06 2023-06-28 Harvard College Synthesis of halichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (en) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 Intermediate for preparing eribulin and preparation method thereof
US11142509B2 (en) 2017-11-09 2021-10-12 Yonsung Fine Chemical Co., Ltd. Intermediate for preparing eribulin mesylate and process for preparing the same
ES2974243T3 (en) 2017-11-15 2024-06-26 Harvard College Macrocyclic compounds and their uses
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11008296B2 (en) 2017-11-21 2021-05-18 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
KR20250057138A (en) 2018-01-03 2025-04-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
JP2021532102A (en) * 2018-07-20 2021-11-25 ドクター レディズ ラボラトリーズ リミテッド Purification process for the preparation of eribulin and its intermediates
US20210340156A1 (en) * 2018-10-09 2021-11-04 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
WO2020110146A1 (en) * 2018-11-28 2020-06-04 Natco Pharma Limited Process for the preparation of high pure eribulin and its mesylate salt
BR112021012138A2 (en) 2018-12-20 2021-08-31 Auransa Inc. PENTAMIDINE ANALOGS AND THEIR USES
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2020255164A1 (en) 2019-06-21 2020-12-24 Council Of Scientific And Industrial Research A chemo-enzymatic process for the preparation of homopropargylic alcohol
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN114729042B (en) 2019-11-07 2026-03-03 卫材R&D管理有限公司 Anti-m Pi Suai day bulin antibody-drug conjugates and methods of use
CN113135876B (en) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 Preparation method of eribulin and intermediate thereof
WO2021148003A1 (en) * 2020-01-22 2021-07-29 上海森辉医药有限公司 Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
KR102377262B1 (en) 2020-05-11 2022-03-22 연성정밀화학(주) Crystalline Eribulin Salt
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd Process for the preparation of eribulin
CN113354659B (en) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 Synthesis of eribulin mesylate
KR20240037267A (en) * 2021-07-22 2024-03-21 상하이 센후이 메디슨 컴퍼니 리미티드 Drug conjugates of eribulin derivatives
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
KR20250133788A (en) * 2023-01-17 2025-09-08 시스트이뮨, 인코포레이티드 Eribulin drug conjugate
WO2024251240A1 (en) 2023-06-09 2024-12-12 徕特康(苏州)生物制药有限公司 Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
CN118834221B (en) * 2023-08-08 2025-10-21 浙江星月药物科技有限公司 A halichondrin B analogue
TW202518024A (en) 2023-10-13 2025-05-01 日商衛材R&D企管股份有限公司 Antibody-drug conjugate metabolites
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof
WO2025228172A1 (en) * 2024-04-28 2025-11-06 上海拓济医药有限责任公司 Eribulin derivative and antibody-drug conjugate thereof, and medical use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
HU227912B1 (en) 1998-06-17 2012-05-29 Eisai R & D Man Co Halichondrin analogs and methods of their use and preparation
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
PL2522663T3 (en) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Intermediates for the preparation of halichondrin B
CN108948039B (en) 2007-10-03 2021-12-31 卫材R&D管理有限公司 Intermediates and methods for the synthesis of halichondrin B analogs
US20090203771A1 (en) 2007-11-16 2009-08-13 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
CN105801599A (en) 2008-04-04 2016-07-27 卫材R&D管理有限公司 Halichondrin b analogs
CN102803254B (en) 2010-01-26 2016-09-14 卫材R&D管理有限公司 furo [3,2-B ] pyran derivatives for halichondrin B analog synthesis

Also Published As

Publication number Publication date
CY2011010I2 (en) 2014-04-09
EP2272839B1 (en) 2012-08-22
NO2011026I1 (en) 2012-01-09
IL139960A0 (en) 2002-02-10
CA2755266C (en) 2014-08-12
US20110172446A1 (en) 2011-07-14
NO2011018I1 (en) 2011-09-26
CA2335300C (en) 2008-10-07
NZ508597A (en) 2004-01-30
BRPI9911326B8 (en) 2021-05-25
RU2245335C2 (en) 2005-01-27
EP1087960A4 (en) 2004-12-01
EP2272840A1 (en) 2011-01-12
EP2272839A1 (en) 2011-01-12
NO328280B1 (en) 2010-01-25
CY1111516T1 (en) 2014-04-09
ZA200007159B (en) 2001-12-04
US6214865B1 (en) 2001-04-10
BR9911326B1 (en) 2015-01-06
AU762998C (en) 2000-01-05
NO2011026I2 (en) 2012-06-11
CN1312804A (en) 2001-09-12
NO20006316L (en) 2001-02-15
NO20093217L (en) 2001-02-15
EP1087960A1 (en) 2001-04-04
CN1216051C (en) 2005-08-24
ATE502932T1 (en) 2011-04-15
WO1999065894A1 (en) 1999-12-23
DE122011100031I1 (en) 2011-12-15
NO20006316D0 (en) 2000-12-12
HUP0103357A2 (en) 2002-01-28
HK1035534A1 (en) 2001-11-30
DE69943296D1 (en) 2011-05-05
FR11C0038I2 (en) 2013-01-11
CA2335300A1 (en) 1999-12-23
CA2632433C (en) 2012-02-07
US6365759B1 (en) 2002-04-02
BR9911326A (en) 2001-04-03
JP4454151B2 (en) 2010-04-21
KR100798600B1 (en) 2008-01-28
CA2632433A1 (en) 1999-12-23
DK1087960T3 (en) 2011-06-14
NO2022019I1 (en) 2022-06-03
CY2011010I1 (en) 2014-04-09
NO331183B1 (en) 2011-10-24
HU227912B1 (en) 2012-05-29
HUP0103357A3 (en) 2002-10-28
EP1087960B1 (en) 2011-03-23
EP2272840B1 (en) 2012-08-22
AU762998B2 (en) 2003-07-10
EP2277873B1 (en) 2012-05-30
KR20010083050A (en) 2001-08-31
US6469182B1 (en) 2002-10-22
PT1087960E (en) 2011-06-17
EP2277873A1 (en) 2011-01-26
LU91854I2 (en) 2011-10-17
JP2002518384A (en) 2002-06-25
FR11C0038I1 (en) 2011-10-14
CA2755266A1 (en) 1999-12-23
AU4573999A (en) 2000-01-05
US8148554B2 (en) 2012-04-03

Similar Documents

Publication Publication Date Title
PT1087960E (en) Macrocyclic analogs and methods of their use and preparation
CA2259148A1 (en) Solid oral dosage forms of valsartan
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
EP1193270A3 (en) Pyrrolobenzodiazepines
AU2002238947A1 (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
WO2001012202A3 (en) Use of chemical chelators as reversal agents for drug-induced neuromuscular block
EP2017269A3 (en) A pharmaceutical compodition comprising form II crystalline Ritonavir and a preparation thereof
WO2002032901A3 (en) Bridged piperazine derivatives
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU4317500A (en) Antibiral compositions containing phorbol derivatives as the main active ingredient
AU5368699A (en) Derivatives of triptolide, and preparation and uses thereof
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
CA2445620A1 (en) Tetracyclic compounds as pde5-inhibitors
AU2001290271A1 (en) Processes for the preparation of perfluoro compounds and derivatives thereof
WO2000064427A3 (en) Lamivudine containing pharmaceutical formulation
AU2001272490A1 (en) Use of galiella lactone
AU6106801A (en) Trans-clitoral administration of therapy
AU2001236361A1 (en) Treatment of asthma with lfm analogues
HUP0400379A3 (en) Tricyclic epoxides and their use for the preparation of pharmaceutically active agents
WO2001060801A3 (en) 9-alkylamino-1-nitroacridine derivatives
AU2002350212A1 (en) Pharmaceutically active compounds and methods of use thereof
HK1058761A (en) Compositions and methods for administration of pharmacologically active compounds
HK1054189A (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
HK1051047A (en) 3'-prodrugs of 2'-deoxy-beta-l-nucleosides
AU2002224951A1 (en) Use of oxabicyclo(2.2.1)heptadiene derivatives as pesticidal agents